Dr. Eng-Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3800 Reservoir Rd Nw
Lombardi Cancer Center
Washington, DC 20007Phone+1 202-444-4948
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
- University of California Davis HealthResidency, Internal Medicine, 1996 - 1999
- Stony Brook University Health Sciences Center School of MedicineClass of 1996
Certifications & Licensure
- DC State Medical License 2000 - 2013
- MD State Medical License 2010 - 2012
Clinical Trials
- Raloxifene in Preventing Breast Cancer in Premenopausal Women Start of enrollment: 1998 Dec 01
- A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Publications & Presentations
PubMed
- 240 citationsCirculating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast CancerMinetta C. Liu, Peter G. Shields, Robert D. Warren, Philip Cohen, Mary Wilkinson
Journal of Clinical Oncology. 2009-11-01 - 292 citationsPertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, rand...Josep Tabernero, Paulo M. Hoff, Lin Shen, Atsushi Ohtsu, Manish A. Shah
The Lancet. Oncology. 2018-10-01 - 149 citationsLong-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-c...Andreas Schneeweiss, Stephen Chia, Tamas Hickish, Vernon Harvey, Alexandru Eniu
European Journal of Cancer. 2018-01-01
Authored Content
- Long-Term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast CancerJanuary 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: